Zepbound for Sleep Apnea: First Drug Approved for OSA

The Short Version: What the FDA Approved

Here is the regulatory picture in plain terms:

This is an FDA-approved indication, and the dates and findings above reflect the public record. Nothing here is medical guidance. Whether this option fits your situation is a clinician-directed question.

What Obstructive Sleep Apnea Is, in Plain Terms

Obstructive sleep apnea is a condition in which the upper airway repeatedly narrows or collapses during sleep, briefly interrupting breathing. Each interruption can fragment sleep and lower blood oxygen, and the pattern can repeat many times an hour. The standard way clinicians grade severity is the apnea-hypopnea index, or AHI: the average number of apneas (full pauses) and hypopneas (partial reductions) per hour of sleep. A higher AHI means more frequent breathing interruptions, which is why AHI sits at the center of both diagnosis and the SURMOUNT-OSA results.

Excess body weight is one well-recognized contributor to OSA, because soft tissue around the airway can make collapse more likely. That connection is the reason the approval is specific to adults who have OSA together with obesity, and it is the mechanistic thread that links a weight-affecting medication like [tirzepatide](/peptides/tirzepatide) to an airway outcome.

How Tirzepatide Works, and Why a Weight Drug Touches Sleep

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In plain terms, it acts on two gut-hormone pathways that influence appetite, satiety, and blood-sugar handling, and in clinical use it is associated with substantial weight reduction. The same molecule is marketed as Zepbound for weight-related indications and as Mounjaro for type 2 diabetes.

The bridge to sleep apnea is body weight. Because excess weight is a contributor to airway collapse in many people with OSA, a medication that reduces body weight can, in the studied population, reduce the frequency of breathing interruptions. That is the logic the SURMOUNT-OSA trials tested directly: they did not just measure pounds lost, they measured whether AHI improved. If you want a structured overview of the compound itself, our [tirzepatide profile](/peptides/tirzepatide) lays out the basics, and the [tirzepatide calculator](/calculators/tirzepatide) is a planning aid for organizing a provider-directed schedule, not a recommendation to start one.

What the SURMOUNT-OSA Trials Showed

The SURMOUNT-OSA program is the reason the approval exists, so it is worth understanding what it measured. The primary outcome was change in AHI, the per-hour count of breathing interruptions. The headline findings, as published:

That last point is important for setting expectations honestly. The trials were not designed to show that a drug replaces a device for everyone. They included people on PAP and people not on PAP, and the AHI improvement was observed in that context. The table below summarizes the key elements as reported.

|---|---|

A note on what these numbers are and are not. They are trial averages from the published program, not a promise about any individual result, and AHI response varies from person to person. This article is reporting the data as published; it is not predicting your outcome, and it is not a substitute for a clinician's assessment of whether the approved indication applies to you.

Where This Fits Alongside CPAP and PAP Therapy

Positive airway pressure, most familiarly CPAP, has long been the mainstay for moderate-to-severe OSA. The 2024 approval does not erase that. As of 2026, tirzepatide is the only FDA-approved drug for OSA, and it is best understood as an added option for a specific population, not a blanket replacement for PAP.

Why the nuance matters: the SURMOUNT-OSA trials deliberately included both people using PAP and people not using it. That design reflects real-world variety rather than a claim that medication makes devices unnecessary. Some people and their clinicians may consider a medication-based approach, some may combine approaches, and some may stay with PAP. Which path fits depends on individual medical factors that only your provider can weigh. The constructive contribution you can make is to bring a clean record of your own data to that conversation, which is where tracking comes in.

What to Track: Biomarkers Worth Monitoring

Whether you are exploring this option, already working with a provider on it, or simply following the space, a clean longitudinal record makes any clinical conversation sharper. People in the OSA-plus-obesity context, working alongside their clinicians, commonly keep an eye on a handful of markers over time. The following are commonly tracked in this setting. None of this is a recommendation to test or treat; it is a list of what is commonly monitored so you can organize your own data and discuss it with your provider.

Tracking these consistently, rather than as scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot; a trend line tells a story. You can browse the full [biomarker library](/biomarkers) for plain-language explanations of each test, and pair lab trends with AHI and weight so the whole picture sits in one place.

[Track your protocol, AHI, weight, and labs over time in one place with MyProtocolStack.](/auth/login?mode=signup)

What This Means If You Are Considering It

If you have moderate-to-severe OSA and obesity and you are wondering whether this approved option fits your situation, the appropriate next step is a conversation with the prescriber or provider who manages your care. This is a clinician-directed decision. The right path depends on your individual medical situation, your current therapy, and factors only a clinician can assess.

What this article will not do is tell you how to obtain anything, what dose to use, or whether to stop any existing therapy. Those are clinical decisions, not content decisions. What you can do on your own is arrive prepared: keep an organized record of your weight, blood pressure, any sleep-study AHI results your clinician shares, and the metabolic markers above. Good data does not make the decision for you, but it makes the conversation with your provider clearer and more grounded.

Frequently Asked Questions

Is tirzepatide (Zepbound) approved for obstructive sleep apnea?

Yes. On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first and only prescription drug for moderate-to-severe obstructive sleep apnea in adults who also have obesity. The approval was based on the SURMOUNT-OSA trials, which measured change in the apnea-hypopnea index (AHI). As of 2026, it remains the only FDA-approved medication for OSA. Whether it fits your situation is a question for your prescriber, since the approval is specific to adults who have both moderate-to-severe OSA and obesity.

How much did tirzepatide improve sleep apnea in the trials?

Across the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index by roughly 25 or more events per hour versus placebo, a large effect on the core measure of OSA severity. Participants also lost up to approximately 20 percent of body weight. These are trial averages from the published program, not a prediction of any individual result, and AHI response varies from person to person.

Does Zepbound replace CPAP for sleep apnea?

Not for everyone. As of 2026, tirzepatide is the only FDA-approved drug for OSA, and it is best understood as an added option rather than a universal replacement for CPAP or other positive airway pressure (PAP) therapy. The SURMOUNT-OSA trials deliberately included both participants who used PAP and those who did not. Whether a medication-based approach, PAP, or a combination fits your situation is a clinician-directed decision.

Why does a weight-loss medication help with sleep apnea?

Excess body weight is a recognized contributor to obstructive sleep apnea because soft tissue around the airway can make collapse during sleep more likely. Tirzepatide is a dual GIP and GLP-1 receptor agonist associated with substantial weight reduction, and in the studied population that weight reduction was linked to fewer breathing interruptions, measured as a lower AHI. That mechanistic link is why the approval is specific to adults who have OSA together with obesity.

What should I track if I am exploring this with my provider?

Markers commonly tracked in this setting include AHI from a sleep study, body weight, blood pressure, and a metabolic panel such as HbA1c and fasting glucose. MyProtocolStack does not provide medical advice and cannot tell you what to take or whether the approved indication applies to you. What you can do on your own is keep an organized record of your protocol, AHI results your clinician shares, weight, and relevant lab markers over time, so your provider conversation is grounded in good data.

Sources

1. U.S. Food and Drug Administration, press announcement: "FDA Approves First Medication for Obstructive Sleep Apnea." https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

2. Eli Lilly and Company, investor news release: "FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity." https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription

3. TCTMD, "Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity." https://www.tctmd.com/news/tirzepatide-gets-fda-approval-sleep-apnea-adults-obesity

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*